Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidence of Chronic Diseases
4.2.2 Increasing Technological Advancements
4.3 Market Restraints
4.3.1 Scarcity of Skilled Labor and Healthcare Professionals
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Analyzers
5.1.1.1 Automated
5.1.1.2 Semi-Automated
5.1.2 Reagents
5.1.2.1 Luminophore Markers
5.1.2.2 Enzymatic Markers
5.1.3 Consumables
5.2 By Application
5.2.1 Oncology
5.2.2 Autoimmune Disorder
5.2.3 Infectious Disease
5.2.4 Cardiovascular Disease
5.2.5 Endocrine Disorders
5.2.6 Others
5.3 By End User
5.3.1 Pharmaceutical and Biotechnology Companies
5.3.2 Hospital and Clinical Laboratories
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 F. Hoffmann-La Roche AG
6.1.2 Mindray Medical International Limited
6.1.3 Siemens Healthcare GmbH
6.1.4 Beckman Coulter Inc. (Danaher Corporation)
6.1.5 DiaSorin S.p.A.
6.1.6 Sysmex Corporation
6.1.7 Randox Laboratories Ltd.
6.1.8 Tosoh Corporation
6.1.9 Shenzhen New Industries Biomedical Engineering Co., Ltd.
6.1.10 BioMerieux


7 MARKET OPPORTUNITIES AND FUTURE TRENDS